23andMe (NASDAQ:ME – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01, Briefing.com reports. The firm had revenue of $92.38 million for the quarter, compared to analyst estimates of $88.40 million. 23andMe had a negative net margin of 103.07% and a negative return on equity of 36.26%. The business’s quarterly revenue was down 8.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.16) earnings per share.
23andMe Stock Up 1.0 %
ME stock opened at $2.06 on Friday. The company’s 50-day simple moving average is $2.12 and its 200-day simple moving average is $2.44. 23andMe has a 52-week low of $1.74 and a 52-week high of $6.31. The firm has a market cap of $941.94 million, a P/E ratio of -2.87 and a beta of 1.37.
Analyst Ratings Changes
Separately, Citigroup dropped their price objective on shares of 23andMe from $3.75 to $2.50 in a report on Friday. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.
Institutional Inflows and Outflows
23andMe Company Profile
23andMe Holding Co operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.
- Get a free copy of the StockNews.com research report on 23andMe (ME)
- 3 Electrical Gear Makers: Hidden Gems Amid Growing Digitization
- Can ULTA’s Defensive Product Line Stand Against This Down Cycle
- A Reversal Is Brewing For Medtronic: Buying The Dip
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
Receive News & Ratings for 23andMe Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 23andMe and related companies with MarketBeat.com's FREE daily email newsletter.